Your session is about to expire
← Back to Search
Bomedemstat + Immunotherapy for Small Cell Lung Cancer
Study Summary
This trial is testing a new drug combo for patients with small cell lung cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 & 2 trial • 90 Patients • NCT03136185Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are allergic to PD-1/PD-L1 targeting drugs.I do not have any ongoing infections that aren't responding to treatment.I can swallow pills.I recently started treatment with specific drugs for small cell lung cancer.I have not received a live vaccine in the last 30 days.Your platelet count is at least 75,000 per microliter without needing a blood transfusion.I am allergic to bomedemstat, LSD1 inhibitors, or similar drugs.I had small cell lung cancer treatment and it came back after finishing treatment.Your hemoglobin level is at least 8.0 grams per deciliter.My blood clotting time is within the normal range and I'm not on blood thinners.I am 18 or older and can sign a consent form.Your hemoglobin level is at least 8.0 grams per deciliter.I haven't used myeloid growth factors in the last 14 days.My cancer hasn't worsened after initial treatment with specific drugs.My cancer hasn't worsened after initial treatment with specific drugs.I had major surgery less than 4 weeks ago or am still dealing with its side effects.You are expected to live for at least 12 more weeks.Your platelet count is at least 75,000 per microliter of blood without needing a transfusion.I have only had four cycles of specific chemotherapy and immunotherapy for my small cell lung cancer.I have small cell lung cancer that hasn't been treated yet.I am 18 or older and can sign a consent form.I agree to use two birth control methods or not have sex during and for 28 days after the study.I've had radiation after starting treatment with platinum-etoposide and an immune checkpoint inhibitor.I am okay with giving blood samples for the study.You are expected to live for at least 12 more weeks.I can take care of myself but might not be able to do heavy physical work.My lung cancer is confirmed to be extensive stage small-cell type.Your blood bilirubin level is not too high, unless you have Gilbert's disease, in which case it can be a little higher.I have or had lung inflammation that needed treatment with strong medication.I have an autoimmune disease and have been on systemic immunosuppressants.I've had 4 cycles of platinum-etoposide and 3-4 cycles of immune therapy for small cell lung cancer.I am currently taking MAOI medications.I haven't taken immunosuppressive drugs in the last 14 days.I am not pregnant, breastfeeding, nor planning to become pregnant or breastfeed during the study.I've had severe side effects from immune therapy that make further treatment unsafe.I cannot stop taking my blood thinner or anti-inflammatory medication even if my platelet count is low.I am not taking any medication that is not allowed in this study.I have a bleeding disorder or a history of very low platelet counts.I expect to undergo brain or chest radiation therapy during the study.I have no GI issues that could affect medication absorption or increase my study risk.I have another cancer that my doctor thinks is important.I have HIV or active hepatitis B/C.I haven't used myeloid growth factors in the last 14 days.My blood clotting time is within normal range and I'm not on blood thinners.I agree to use birth control during and for 28 days after the study treatment.My small cell lung cancer progressed after initial treatment.My kidney function, measured by GFR, is adequate.My liver enzymes are within the acceptable range for the trial.My lung cancer is confirmed to be extensive stage small-cell type.I am able to get out of my bed or chair and move around.
- Group 1: Treatment (bomedemstat, atezolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical trial a pioneering endeavor?
"To date, Baxter Healthcare Corporation has conducted 104 clinical trials for Bomedemstat in 1650 cities located within 74 nations. The first trial commenced in 2007 with 4640 participants and concluded its Phase 4 drug approval stage. Currently there are 365 active studies centred around this pharmaceutical product."
Is this research currently accepting new participants?
"Affirmative. Clinicaltrials.gov data indicates that this medical trial, which was initially listed on April 11th 2022, is currently in the process of recruiting patients. In total, 34 individuals are required across 1 clinical site for successful completion of the study."
How many participants are being recruited into this experiment?
"Affirmative! The information on clinicaltrials.gov highlights the fact that this medical trial is actively pursuing participants. This research was first made public on April 11th 2022 and has been recently updated as of June 22nd 2022. 34 patients are needed to be enrolled from one location."
Have any previous investigations made use of Bomedemstat?
"Presently, there are 365 clinical trials active for Bomedemstat; 71 of those have progressed to Phase 3. While the bulk of these experiments are situated in Basel, BS, a total of 18418 sites worldwide are conducting research on this medication."
For what reasons is Bomedemstat often prescribed?
"Bomedemstat can be used therapeutically to reduce weight gain. It has also been successfully employed by medical professionals in the treatment of small cell lung cancer (sclc), malignant neoplasms, and amino acid supplementation."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
What site did they apply to?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger